Clinical Trial Update: Topical rVA576 for Treatment of Atopic Keratoconjunctivitis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of topical rVA576 for atopic keratoconjunctivitis, vernal keratoconjunctivitis, and allergic conjunctivitis was terminated, with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis
• Atopic Keratoconjunctivitis
• Vernal Keratoconjunctivitis

Drugs mentioned

• rVA576 (rVA576)

Snippet

Sponsor: AKARI Therapeutics | Conditions: Keratoconjunctivitis, Atopic, Keratoconjunctivitis, Vernal | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-02-27